Biosig Technologies Inc
NASDAQ:STEX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Biosig Technologies Inc
NASDAQ:STEX
|
US |
|
R
|
Raymond James Financial Inc
F:RJF
|
US |
|
G
|
Globant SA
LSE:0RIX
|
LU |
Biosig Technologies Inc
Biosig Technologies is a medical technology company that builds tools for cardiac electrophysiology, the specialty that studies and treats abnormal heart rhythms. Its main product is the PURE EP system, a recording and signal-processing platform used in hospital electrophysiology labs during procedures such as mapping and ablation. The company focuses on making the heart’s electrical signals clearer so doctors can work with more usable data. Its customers are hospitals, electrophysiologists, and other medical centers that run heart-rhythm procedures. Biosig makes money by selling or licensing its system and by earning related product and service revenue tied to installations, upgrades, and support. In practice, it sits between the hospital lab and the procedure itself, supplying the hardware and software that doctors use during the case. What makes the business different is that it is not a broad medical device maker. It is concentrated on a narrow part of cardiology where signal quality matters a lot, and its value comes from capturing and processing noisy electrical data better than older recording setups. That gives it a specialized role in the workflow of electrophysiology labs rather than in everyday hospital care.
Biosig Technologies is a medical technology company that builds tools for cardiac electrophysiology, the specialty that studies and treats abnormal heart rhythms. Its main product is the PURE EP system, a recording and signal-processing platform used in hospital electrophysiology labs during procedures such as mapping and ablation. The company focuses on making the heart’s electrical signals clearer so doctors can work with more usable data.
Its customers are hospitals, electrophysiologists, and other medical centers that run heart-rhythm procedures. Biosig makes money by selling or licensing its system and by earning related product and service revenue tied to installations, upgrades, and support. In practice, it sits between the hospital lab and the procedure itself, supplying the hardware and software that doctors use during the case.
What makes the business different is that it is not a broad medical device maker. It is concentrated on a narrow part of cardiology where signal quality matters a lot, and its value comes from capturing and processing noisy electrical data better than older recording setups. That gives it a specialized role in the workflow of electrophysiology labs rather than in everyday hospital care.
